Risk Adapted Treatment of Myelofibrosis: A Focus on Quality-of-Life (webcourse)

Myelofibrosis is a rare myeloproliferative neoplasm associated with poor outcomes. Because early stages of disease are associated with minimal symptoms, most patients are diagnosed with advanced disease. In these patients, overall survival can be short and the risk of transformation to leukemia is high. To improve patient outcomes, it is important that high-risk patients with advanced disease are identified early and receive appropriate treatment. While historically there have been limited treatment options for advanced myelofibrosis, several novel JAK inhibitors have been approved in the past decade that significantly improve disease symptoms and overall survival, improving patient quality of life. However, use of these agents can be challenging, both in determining the optimal treatment selection, identifying when to switch therapies, and minimizing the impact of disease symptoms and treatment-related adverse events on patient quality-of-life.

This activity, Risk Adapted Treatment of Myelofibrosis: A Focus on Quality-of-Life, will provide hematologists and oncologists with important information on the role of risk stratification in guiding treatment selection, efficacy and safety data for current and emerging myelofibrosis therapies, and strategies for integrating these agents into clinical practice in a way that prolongs survival, minimizes adverse events, and improves patient quality-of-life.

Jointly provided by

This program is supported by an educational grant from Bristol Myers Squibb.